Personal tools

MCL coexpression mm9:1023: Difference between revisions

From FANTOM5_SSTAR

Jump to: navigation, search
No edit summary
No edit summary
Line 6: Line 6:
|ontology_enrichment_disease=DOID:0060100!1.56e-09!3;DOID:4045!1.56e-09!3
|ontology_enrichment_disease=DOID:0060100!1.56e-09!3;DOID:4045!1.56e-09!3
|ontology_enrichment_uberon=UBERON:0002384!1.50e-15!46
|ontology_enrichment_uberon=UBERON:0002384!1.50e-15!46
|tfbs_overrepresentation_for_novel_motifs=0.438063,0.369498,0.411716,0.480627,0.299217,0.495263,0.587291,0.594722,0.616096,0.478312,0.542749,0.575086,0.59526,0.599731,0.315771,0,0.795315,0.291368,0.561256,0.361892,0.374752,0.586604,0.598814,0.29769,0.419327,0.62766,1.0368,0.516511,0.344372,0.446946,0.50223,0.897561,0.289148,0.498917,0.316253,0.248902,0.279977,0.57142,0.717242,0.652422,0.800988,0.507468,0.258106,0.851774,0.822425,0.469348,0.714592,1.31862,0.478447,0.347313,0.777641,0.654933,0.431711,1.04034,1.0579,0.606984,0.356236,0.56214,1.00328,0.604914,0.877332,0.664501,0.642748,0.766235,0.618279,0.807219,1.19497,1.54543,0.872612,1.39786,0.392734,0.608073,0.0869413,1.09164,0.17012,0.936963,0.963958,0.703064,0.859987,0.98764,0.212973,0.812889,0.663039,0.580284,0.975495,0.146394,0.164297,0.447265,0.719558,1.70793,1.26498,0.980512,0.910485,0.305079,0.254625,0.237542,0.589174,0.913319,0.71485,0.79664,0.280055,0.897279,1.02279,0.778243,0.777175,0.507021,0.837607,0.528416,0.383871,0.376549,0.430942,2.33607,0.380122,0.547992,1.27206,0.293461,0.418498,0.484437,0.796633,0.276329,1.09707,0.745011,0.629509,0.702145,1.32639,0.863723,0.595563,0.903645,1.19345,0.308038,1.00568,0.473246,1.16374,0.620831,1.29374,0.0806013,0.446555,0.508896,1.24438,2.07659,1.67603,1.19971,0.641722,0.908128,0.770616,0.507927,0.717753,2.03691,0.448938,0.813943,0.147909,0.0736236,1.04192,0.681896,0.619892,1.12411,0.655955,0.327731,0.435579,0.446272,1.25393,0.974632,0.864173,0.428662,0.767269,1.48714,1.3969,0.573477,0.0907999
}}
}}

Revision as of 19:16, 26 November 2012


Phase1 CAGE Peaks

 Short description
Mm9::chr10:41197008..41197040,-p@chr10:41197008..41197040
-
Mm9::chr10:59395547..59395567,+p@chr10:59395547..59395567
+
Mm9::chr14:63456596..63456607,+p3@Wdfy2
Mm9::chr2:75523561..75523580,-p@chr2:75523561..75523580
-
Mm9::chr3:90416194..90416218,+p@chr3:90416194..90416218
+
Mm9::chr5:118928589..118928600,+p@chr5:118928589..118928600
+
Mm9::chr8:124956346..124956356,-p4@Cyba


Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data


no results for this coexpression

Relative expression of the co-expression cluster over median <br>Analyst:





Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br>cell_data<br>uberon_data<br>disease_data<br>


Cell Type
Ontology termp-valuen
hematopoietic cell2.99e-2132
hematopoietic oligopotent progenitor cell2.99e-2132
hematopoietic stem cell2.99e-2132
angioblastic mesenchymal cell2.99e-2132
hematopoietic multipotent progenitor cell2.99e-2132
connective tissue cell1.50e-1546
mesenchymal cell1.50e-1546
motile cell3.26e-1454
lymphoid lineage restricted progenitor cell7.32e-1312
lymphocyte8.87e-1213
common lymphoid progenitor8.87e-1213
stem cell9.74e-1297
leukocyte4.08e-1117
nongranular leukocyte4.08e-1117
T cell8.49e-1111
pro-T cell8.49e-1111
common myeloid progenitor9.96e-1119
hematopoietic lineage restricted progenitor cell1.53e-1025
nucleate cell2.42e-0916
somatic stem cell5.43e-0991
multi fate stem cell5.43e-0991
mature alpha-beta T cell4.78e-079
alpha-beta T cell4.78e-079
immature T cell4.78e-079
mature T cell4.78e-079
immature alpha-beta T cell4.78e-079
granulocyte monocyte progenitor cell5.94e-077

Uber Anatomy
Ontology termp-valuen
connective tissue1.50e-1546

Disease
Ontology termp-valuen
musculoskeletal system cancer1.56e-093
muscle cancer1.56e-093


TFBS overrepresentation<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data


Novel motifs




JASPAR motifs


Motifs-log10(p-value)

{{{tfbs_overrepresentation_jaspar}}}